Mag-3 Kit

Mertiatide, the active ingredient in Mag-3 Kit, is a compound presented as an intravenous preparation for use under medical supervision. It is employed in specialized clinical settings as directed by a healthcare professional and supplied in a sterile kit format suitable for hospital use.

GNH USA supplies Mag-3 Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mertiatide is utilized in clinical protocols that require intravenous administration for diagnostic or therapeutic purposes.

Renal imaging: used as part of protocols to assess kidney function when ordered by a physician. Cardiac stress testing: employed in certain intravenous protocols under specialist supervision. Research applications: applied in clinical studies investigating physiological responses.

Adverse reactions may occur following intravenous administration of Mertiatide. Monitoring during and after infusion is recommended.

Common Side Effects: - Mild flushing or warmth at the infusion site. - Transient headache. - Nausea or mild gastrointestinal discomfort. - Low-grade fever. - Brief hypotension. - Dizziness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Significant drop in blood pressure requiring intervention. - Cardiac arrhythmia. - Acute kidney injury. - Pulmonary edema. - Hemolysis.

Prior to administration, clinicians should assess patient history and current condition.

Allergy assessment: confirm no known hypersensitivity to Mertiatide or excipients. Renal function: evaluate baseline kidney status before use. Cardiovascular monitoring: observe for hypotension or arrhythmias during infusion. Pregnancy and lactation: weigh potential benefits against unknown risks. Drug interactions: review concomitant medications for possible infusion-related effects. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mertiatide may interact with other agents administered intravenously or those affecting cardiovascular stability.

Major Interactions (Avoid): - Concurrent use of potent vasodilators that may exacerbate hypotension. - Known allergens that cross‑react with formulation components. - High‑dose diuretics that could precipitate renal compromise.

Moderate Interactions (Monitor Closely): - Antihistamines that may mask early signs of allergic reaction. - Beta‑blockers influencing heart rate response. - NSAIDs that could affect renal perfusion. - Other diagnostic agents administered within the same session.